In8bio Inc (INAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, In8bio Inc (INAB) has a cash flow conversion efficiency ratio of -0.267x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.52 Million) by net assets ($13.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
In8bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how In8bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read INAB liabilities breakdown for a breakdown of total debt and financial obligations.
In8bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of In8bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cheetah Holdings Bhd
KLSE:7209
|
-0.096x |
|
Idomoo Ltd
TA:IDMO
|
0.085x |
|
West International AB
ST:WPAY
|
0.282x |
|
Phapros Tbk PT
JK:PEHA
|
0.051x |
|
Asia Sejahtera Mina Tbk
JK:AGAR
|
0.095x |
|
Winhitech Co Ltd
KQ:192390
|
0.058x |
|
Sapura Resources Bhd
KLSE:4596
|
0.090x |
|
RPCG Public Company Limited
BK:RPC
|
-0.007x |
Annual Cash Flow Conversion Efficiency for In8bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of In8bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see In8bio Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.48 Million | $-24.15 Million | -1.668x | -78.21% |
| 2023-12-31 | $24.94 Million | $-23.34 Million | -0.936x | +11.79% |
| 2022-12-31 | $22.73 Million | $-24.12 Million | -1.061x | -199.92% |
| 2021-12-31 | $38.18 Million | $-13.51 Million | -0.354x | +9.13% |
| 2020-12-31 | $18.32 Million | $-7.13 Million | -0.389x | -102.81% |
| 2019-12-31 | $-346.00K | $-4.80 Million | 13.876x | +2428.66% |
| 2018-12-31 | $4.65 Million | $-2.77 Million | -0.596x | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candid… Read more